Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency (IGHD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00630487|
Recruitment Status : Terminated (See termination reason in detailed description.)
First Posted : March 7, 2008
Results First Posted : January 27, 2011
Last Update Posted : March 4, 2013
|Condition or disease||Intervention/treatment||Phase|
|Growth Hormone Deficiency||Drug: Placebo Drug: Somatropin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Prospective, Randomized, Double Blind Placebo-Controlled Trial On The Efficacy Of Growth Hormone Replacement Therapy In Adult Patients With Isolated Growth Hormone Deficiency (PRO ISO-GHD Study)|
|Study Start Date :||May 2008|
|Actual Primary Completion Date :||October 2008|
|Actual Study Completion Date :||October 2008|
|Placebo Comparator: Placebo||
Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.
|Active Comparator: Verum||
Fixed doses for patients: MALE: < 45y 0,4 mg, > 45y 0,2mg FEMALE: < 45y 0,5mg, >45y 0,3mg. for the first 4 weeks half of the dose will be given. After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range. In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks). At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.
- Change of Visceral Fat Mass Assessed by Magnetic Resonance Imaging Scanning (MRI) [ Time Frame: Baseline, 52 weeks ]Fat measurements carried out with the subjects lying in a supine position in a MRI scanner. Measurements of regional body fat obtained between the level of the coccygeal bone and the 2nd or 3rd lumbar vertebra.
- Change in Visceral Fat Mass in Subgroups [ Time Frame: Baseline, 52 weeks, 78 weeks ]Change in visceral fat mass in subgroups. Subgroup 1: isolated GHD due to surgery and/or irradiation of pituitary adenoma and suprasellar tumors. Subgroup 2: history of traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH).
- Change From Baseline in Anthropometric Parameters (Height) [ Time Frame: Baseline, 52 weeks, 78 weeks ]
- Change From Baseline in Anthropometric Parameters (Weight) [ Time Frame: Baseline, 52 weeks, 78 weeks ]
- Change From Baseline in Anthropometric Parameters (Waist Circumference) [ Time Frame: Baseline, 52 weeks, 78 weeks ]
- Change From Baseline in Alertness (Testbatterie Zur Aufmerksamkeitsprüfung [TAP]) and Memory (Auditory Verbal Learning Test [AVLT]) [ Time Frame: Baseline, Week 52, Week 78 ]Alertness: software-based neuropsychological assessment for response time and errors. Memory: analysis of learning and retention using 5-trial presentation of 15-word list (A), single presentation of interference list (B), 2 postinterference recall trials - 1 immediate, 1 delayed - and recognition of the target words with distractors (C). Performance variables were immediate word span under overload conditions, final acquisition level, amount learned in 5 trials, interference, delayed recall, and recognition (implicit learning).
- Change From Baseline in Blood Pressure [ Time Frame: Baseline, Week 52, Week 78 ]Blood pressure was measured seated, the subject's arm supported at the level of the heart, and recorded to the nearest mm Hg. The same arm (preferably the dominant arm) was used throughout the trial. The subject was seated for 5 minutes before the blood pressure was obtained. Use of an automated device could have been used for measuring blood pressure.
- Change From Baseline in Heart Rate [ Time Frame: Baseline, Week 52, Week 78 ]The use of an automated device for measuring pulse rate was acceptable, although, when done manually, pulse rate was measured in the brachial/radial artery for at least 30 seconds.
- Change in Executive Function and Memory in Subgroups [ Time Frame: Baseline, Week 52, Week 78 ]Change in executive function and memory in subgroups. Subgroup 1: isolated Growth Hormone Deficiency (GHD)due to surgery and/or irradiation of pituitary adenoma and suprasellar tumors. Subgroup 2: history of traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH). Median reaction time, the total number of errors, the number of omissions and the number of false positive reactions.
- Change From Baseline in Safety Laboratory Assessments [ Time Frame: Baseline, Week 52, Week 78 ]Prespecified safety laboratory assessments evaluated for change or no change from baseline. Possible responses were Yes/No.
- Change From Baseline in Homeostasis Model Assessment (HOMA)-Index [ Time Frame: Baseline, Week 52, Week 78 ]HOMA index is calculated by 1 of 2 methods: HOMA-Index = fasting insulin measured in microunits per milliliter (µU/ml) times fasting glucose measured in milligrams per deciliter mg/dl) divided by 405 or HOMA-Index = fasting insulin (µU/ml) times fasting glucose measured in millimoles per liter (mmol/l) divided by 22.5.
- Change From Baseline in Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) [ Time Frame: Baseline, Week 52, Week 78 ]Participant self administered questionnaire consisting of 25 items that evoke yes or no answers. A score of 1 is given to each item affirmed and these are summed to give the total score. The maximum score is 25, which represents a poor quality of life. The minimum score is 0, which represents a good quality of life.
- Change From Baseline in Short Form (36) Health Survey (SF36) [ Time Frame: Baseline, Week 52, Week 78 ]Participant self administered questionnaire that measures each of the following eight health concepts: Physical Functioning (PF); Role-Physical (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role-Emotional (RE); Mental Health (MH) as well as a reported Health Transition item (HT). Scale range 0 to 100, higher scores indicate a better health-related quality of life.
- Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) [ Time Frame: Baseline, Week 52, Week 78 ]Participant self-administered questionnaire EQ-5D, a 2 part generic health status instrument. The first part consists of 5 descriptors of current health state: mobility, self care, usual activities, pain/discomfort and anxiety/depression. Scores are assigned on a three-level scale (1= no problem, 2= some problem, 3= extreme problem). The second part was an overall rating of the participant's current health state using a 20 cm Visual Analogue Scale (EQ-VAS) with endpoints labelled 'best imaginable health state' and 'worst imaginable health state'.
- Change From Baseline in Cardiovascular Risk Factors [ Time Frame: Baseline, Week 52, Week 78 ]Change in values of laboratory tests indicative of possible cardiovascular risk factors: high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides, N-terminal pro brain natriuretic peptide)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00630487
|Pfizer Investigational Site|
|Bad Aibling, Germany, 83043|
|Pfizer Investigational Site|
|Muenchen, Germany, 80804|
|Study Director:||Pfizer CT.gov Call Center||Pfizer|